Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

August 18th 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

Dr Islam on the Current and Expanding Role of Pirtobrutinib in MCL

August 18th 2023

Prioty Islam, MD, MSc, discusses how the FDA approval of the noncovalent BTK inhibitor pirtobrutinib has transformed the treatment of patients with mantle cell lymphoma, and where this agent fits in to the current treatment armamentarium.

Pirtobrutinib Demonstrates Durable Efficacy in Pretreated Mantle Cell Lymphoma

August 6th 2023

Nirav Shah, MD, discusses the efficacy of pirtobrutinib in patients with mantle cell lymphoma who were previously treated with a covalent BTK inhibitor and progressed, and outlines the next steps for exploration of the noncovalent BTK inhibitor in this population.

Future Directions in the Treatment of Mantle Cell Lymphoma

August 3rd 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

August 2nd 2023

Swetha Kambhampati, MD, explains the need for real-world data on responses to brexu-cel in patients with relapsed/refractory MCL, compares safety and efficacy data from the subgroup analysis with prior results from ZUMA-2, and discusses how these findings support more long-term follow-up in this population.

Wealth of BTK Inhibitors Provides Tolerable, Individualized Treatment Options in CLL and MCL

August 2nd 2023

Prioty Islam, MD, MSc, reviews the benefits of using covalent BTK inhibitors in CLL and MCL; considerations for choosing first-generation vs next-generation covalent BTK inhibitors in patients with these B-cell malignancies; and the potential future role for ibrutinib in the CLL treatment paradigm.

Earlier-Line Pirtobrutinib Investigation May Alter BTK Inhibitor Sequencing in CLL and MCL

August 1st 2023

Prioty Islam, MD, MSc, discusses findings from the BRUIN trial, highlights the potential benefits of using noncovalent BTK inhibitors instead of or before covalent BTK inhibitors in patients with MCL or CLL, and previewed ongoing clinical trials investigating this class of agents in earlier treatment lines in these populations.

Dr Islam on Clinical Decisions Regarding BTK Inhibitor Use in MCL and CLL

August 1st 2023

Prioty Islam, MD, MSc, discusses the importance of shared decision making between patients and clinicians when selecting among available BTK inhibitors in the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

August 1st 2023

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting.

Dr Shah on the Background of the BRUIN Trial in Relapsed/Refractory MCL

July 28th 2023

Nirav N. Shah, MD, discusses the background of the phase 1/2 BRUIN trial of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma.

Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

July 28th 2023

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma

July 28th 2023

Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr Danilov on Treatment Considerations in High-Risk MCL

July 24th 2023

Alexey Danilov, MD, PhD, discusses considerations for varying treatment approaches in patients with high-risk mantle cell lymphoma.

Dr Burke on Ongoing Investigations of Targeted Therapy Regimens in MCL

July 20th 2023

John M. Burke, MD, discusses several ongoing or upcoming investigations of targeted therapy in mantle cell lymphoma.

Real-World Analysis Shows Brexu-Cel Elicits Higher CR Rate in Patients With R/R MCL Given Fewer Lines of Prior Therapy

July 20th 2023

Nausheen Ahmed, MD, explains the rationale for examining real-world outcomes observed with the use of brexu-cel in the treatment of patients with relapsed/refractory mantle cell lymphoma, details the key efficacy and safety findings from the overall population and different subgroups, and discusses what will be gained with longer follow-up of the study.

Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

July 20th 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma

July 20th 2023

Experts explain the role of maintenance therapy in mantle cell lymphoma and how it impacts the risk of disease progression.

Dr Ahmed on the Rationale for Investigating Real-World Outcomes of Brexu-Cel in R/R MCL

July 19th 2023

Nausheen Ahmed, MD, discusses the rationale for investigating real-world outcomes of patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

Phase 1b Data Support Continued Investigation of Acalabrutinib Plus BR in MCL

July 19th 2023

Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.

Dr Danilov on Questions Remaining Across the Treatment Landscape of MCL

July 17th 2023

Alexey Danilov, MD, PhD, discusses lingering questions that remain across the treatment landscape of mantle cell lymphoma.